Search

China has entered the booming stage of urban rail transit. Suspended monorail system, which belongs to urban rail transit with low traffic volume, is under development. Adaptability and technical feasibility of suspended monorail are analyzed on the basis of train capacity, technical features and construction cost. Operational features of symmetrical suspended monorail systems in Germany and Japan are introduced. Capacity adaptability of the monorail is calculated under four-parameter combined cases, which are vehicle size, seat layout, train marshalling and capacity principles. The trains with width 2.4 m∼2.6 m and marshalling cars 2∼3, are suggested in domestic. Compared to modern tram, bus rapid transit (BRT), and metro, the monorail has unique advantages in technology, engineering construction and cost, and it becomes new development of urban rail transit. Learn from development of mid-low speed maglev traffic, and the monorail will be successfully brought to market.

The prognosis for adults with relapsed acute lymphoblastic leukemia is poor. We sought to determine whether inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, results in better outcomes in patients with relapsed or refractory acute lymphoblastic leukemia than does standard therapy.In this phase 3 trial, we randomly assigned adults with relapsed or refractory acute lymphoblastic leukemia to receive either inotuzumab ozogamicin (inotuzumab ozogamicin group) or standard intensive chemotherapy (standard-therapy group). The primary end points were complete remission (including complete remission with incomplete hematologic recovery) and overall survival.Of the 326 patients who underwent randomization, the first 218 (109 in each group) were included in the primary intention-to-treat analysis of complete remission. The rate of complete remission was significantly higher in the inotuzumab ozogamicin group than in the standard-therapy group (80.7% [95% confidence interval {CI}, 72.1 to 87.7] vs. 29.4% [95% CI, 21.0 to 38.8], P0.001). Among the patients who had complete remission, a higher percentage in the inotuzumab ozogamicin group had results below the threshold for minimal residual disease (0.01% marrow blasts) (78.4% vs. 28.1%, P0.001); the duration of remission was longer in the inotuzumab ozogamicin group (median, 4.6 months [95% CI, 3.9 to 5.4] vs. 3.1 months [95% CI, 1.4 to 4.9]; hazard ratio, 0.55 [95% CI, 0.31 to 0.96]; P=0.03). In the survival analysis, which included all 326 patients, progression-free survival was significantly longer in the inotuzumab ozogamicin group (median, 5.0 months [95% CI, 3.7 to 5.6] vs. 1.8 months [95% CI, 1.5 to 2.2]; hazard ratio, 0.45 [97.5% CI, 0.34 to 0.61]; P0.001); the median overall survival was 7.7 months (95% CI, 6.0 to 9.2) versus 6.7 months (95% CI, 4.9 to 8.3), and the hazard ratio was 0.77 (97.5% CI, 0.58 to 1.03) (P=0.04). In the safety population, the most frequent grade 3 or higher nonhematologic adverse events with inotuzumab ozogamicin were liver-related. Veno-occlusive liver disease of any grade occurred in 15 patients (11%) who received inotuzumab ozogamicin and in 1 patient (1%) who received standard therapy.The rate of complete remission was higher with inotuzumab ozogamicin than with standard therapy, and a higher percentage of patients in the inotuzumab ozogamicin group had results below the threshold for minimal residual disease. Both progression-free and overall survival were longer with inotuzumab ozogamicin. Veno-occlusive liver disease was a major adverse event associated with inotuzumab ozogamicin. (Funded by Pfizer; INO-VATE ALL ClinicalTrials.gov number, NCT01564784.).

For analyzing samples of curves, Kneip and Gasser proposed a “structural analysis” for estimating an average curve which gives the average amplitude and dynamics of the sample curves. An important step of their method is the estimation of the warping functions in order to eliminate the differences in dynamics between different curves. It is of interest to compute confidence bounds for the structural average curve. First, we derive the necessary asymptotic results to obtain confidence intervals based on asymptotic normality. Due to the complex form of the asymptotic formulas and due to their asymptotic nature, bootstrap procedures are studied in a second step. A small archive SACI (Structural Averaging and Confidence Intervals), written in Fortran, can be obtained from the Web site “http://www.unizh.ch/biostat” to compute the structural average curve, to construct confidence regions at a structural point and to compute confidence bars at other points.